Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 2.03T |
| Revenue (ttm) | 1.54T |
| Net Income (ttm) | 93.19B |
| Shares Out | 11.51M |
| EPS (ttm) | 8,098.18 |
| PE Ratio | 21.77 |
| Forward PE | 12.71 |
| Dividend | 600.00 (0.34%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 52,482 |
| Average Volume | 42,316 |
| Open | 178,000 |
| Previous Close | 176,300 |
| Day's Range | 173,000 - 186,400 |
| 52-Week Range | 109,000 - 199,400 |
| Beta | 0.06 |
| RSI | 53.38 |
| Earnings Date | Feb 9, 2026 |
About Daewoong Pharmaceutical
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ... [Read more]
Financial Performance
In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.
Financial StatementsNews
AEON Biopharma announces execution of exchange agreement with Daewoong Pharmaceutical
Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis
Sun Pharmaceutical Industries Limited has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, a novel treatment for Erosive Esophagitis. FEXUCLUE® is a Potassium-Competitive Acid Bl...